Fulton Breakefield Broenniman’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.04M Sell
5,785
-97
-2% -$34.6K 0.13% 76
2025
Q4
$1.93M Sell
5,882
-47
-0.8% -$14.9K 0.12% 75
2025
Q3
$1.67M Buy
5,929
+88
+2% +$25.5K 0.11% 81
2025
Q2
$1.63M Buy
5,841
+55
+1% +$15.6K 0.11% 80
2025
Q1
$1.8M Buy
5,786
+1
+0% +$295 0.13% 75
2024
Q4
$1.51M Sell
5,785
-14
-0.2% -$4.15K 0.11% 84
2024
Q3
$1.87M Sell
5,799
-680
-10% -$222K 0.13% 78
2024
Q2
$2.02M Buy
6,479
+76
+1% +$22.3K 0.15% 71
2024
Q1
$1.82M Sell
6,403
-910
-12% -$266K 0.14% 73
2023
Q4
$2.11M Sell
7,313
-821
-10% -$224K 0.17% 65
2023
Q3
$2.19M Sell
8,134
-143
-2% -$35.7K 0.19% 68
2023
Q2
$1.84M Hold
8,277
0.15% 71
2023
Q1
$2M Sell
8,277
-28
-0.3% -$6.87K 0.17% 72
2022
Q4
$2.18M Buy
8,305
+1,160
+16% +$311K 0.19% 70
2022
Q3
$1.61M Sell
7,145
-181
-2% -$43.9K 0.15% 72
2022
Q2
$1.78M Buy
+7,326
New +$1.8M 0.15% 76
2022
Q1
Sell
-8,353
Closed -$1.88M 166
2021
Q4
$1.88M Buy
8,353
+1,855
+29% +$392K 0.14% 76
2021
Q3
$1.38M Sell
6,498
-278
-4% -$64K 0.12% 74
2021
Q2
$1.65M Buy
6,776
+51
+0.8% +$12.5K 0.14% 72
2021
Q1
$1.67M Buy
6,725
+714
+12% +$170K 0.15% 70
2020
Q4
$1.38M Sell
6,011
-852
-12% -$196K 0.17% 67
2020
Q3
$1.74M Sell
6,863
-155
-2% -$38.4K 0.2% 62
2020
Q2
$1.66M Hold
7,018
0.2% 62
2020
Q1
$1.42M Sell
7,018
-477
-6% -$104K 0.21% 61
2019
Q4
$1.81M Sell
7,495
-152
-2% -$33.5K 0.21% 72
2019
Q3
$1.48M Buy
+7,647
New +$1.47M 0.19% 75
2019
Q1
Sell
-14,415
Closed -$2.81M 102
2018
Q4
$2.81M Sell
14,415
-1,177
-8% -$230K 0.5% 59
2018
Q3
$3.23M Sell
15,592
-800
-5% -$158K 0.5% 61
2018
Q2
$3.03M Sell
16,392
-23,912
-59% -$4.23M 0.48% 66
2018
Q1
$6.87M Sell
40,304
-18
-0% -$3.3K 1.19% 45
2017
Q4
$7.01M Buy
40,322
+134
+0.3% +$23.7K 1.18% 42
2017
Q3
$7.49M Sell
40,188
-1
-0% -$177 1.31% 33
2017
Q2
$6.92M Sell
40,189
-79
-0.2% -$12.8K 1.24% 39
2017
Q1
$6.61M Buy
40,268
+1,204
+3% +$200K 1.23% 37
2016
Q4
$5.71M Sell
39,064
-890
-2% -$134K 1.13% 40
2016
Q3
$6.67M Sell
39,954
-895
-2% -$151K 1.35% 34
2016
Q2
$6.21M Buy
40,849
+162
+0.4% +$25.2K 1.27% 35
2016
Q1
$6.1M Buy
40,687
+1,749
+4% +$260K 1.34% 32
2015
Q4
$6.32M Buy
38,938
+302
+0.8% +$47.5K 1.4% 28
2015
Q3
$5.34M Sell
38,636
-4,403
-10% -$694K 1.26% 35
2015
Q2
$6.61M Buy
43,039
+1,131
+3% +$181K 1.45% 26
2015
Q1
$6.7M Buy
41,908
+925
+2% +$146K 1.49% 25
2014
Q4
$6.53M Buy
40,983
+236
+0.6% +$36.8K 1.43% 27
2014
Q3
$5.72M Buy
40,747
+32
+0.1% +$4.18K 1.34% 34
2014
Q2
$4.82M Sell
40,715
-64
-0.2% -$7.41K 1.17% 36
2014
Q1
$5.03M Buy
40,779
+642
+2% +$77.9K 1.3% 32
2013
Q4
$4.58M Sell
40,137
-2,289
-5% -$260K 1.21% 31
2013
Q3
$4.75M Buy
42,426
+1,242
+3% +$135K 1.28% 29
2013
Q2
$4.06M Buy
+41,184
New +$4.27M 1.19% 32

Other funds holding AMGN

Fulton Breakefield Broenniman's AMGN Position: Q1 2026 in Review

Fulton Breakefield Broenniman reduced its Amgen (AMGN) stake by 1.6% in Q1 2026, selling an estimated $34.6K and leaving 5,785 shares worth $2.04M. The position accounts for 0.13% of the portfolio, ranked #76.

Fulton Breakefield Broenniman first reported a position in AMGN in Q2 2013 and has held it in 49 quarters since. The position peaked at $7.49M in Q3 2017. 3,126 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Fulton Breakefield Broenniman held 5,785 shares of Amgen worth $2.04M as of Q1 2026.
  • Fulton Breakefield Broenniman sold 97 Amgen shares in Q1 2026, an estimated $34.6K.
  • Amgen made up 0.13% of Fulton Breakefield Broenniman's portfolio in Q1 2026, its #76 holding.
  • Fulton Breakefield Broenniman first reported a position in Amgen in Q2 2013 and has held it in 49 quarters since.
  • Fulton Breakefield Broenniman's Amgen position peaked at $7.49M in Q3 2017.
  • 3,126 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Fulton Breakefield Broenniman's 13F filing for Q1 2026, filed 27 Apr 2026.